Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | LPL | P06858 | 3/20 | 0.56 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402451 | 1.00 | MAOA (0.59) | MAOAMAOBCYP19A1LPLLIPG | |
| SCHEMBL28489702 | 0.98 | LPL (0.57) | MAOAMAOBCYP19A1LPLLIPG | |
| SCHEMBL352479 | 0.98 | LPL (0.57) | MAOAMAOBCYP19A1LPLLIPG | |
| SCHEMBL28902509 | 0.98 | LPL (0.57) | MAOAMAOBCYP19A1LPLLIPG | |
| SCHEMBL9168076 | 0.98 | LPL (0.57) | MAOAMAOBCYP19A1LPLLIPG | |
| SCHEMBL6628922 | 0.98 | LPL (0.57) | MAOAMAOBCYP19A1LPLLIPG | |
| SCHEMBL3625874 | 0.98 | LPL (0.57) | MAOAMAOBCYP19A1LPLLIPG | |
| SCHEMBL29402837 | 0.98 | LPL (0.57) | MAOAMAOBCYP19A1LPLLIPG | |
| SCHEMBL16236477 | 0.98 | LPL (0.57) | MAOAMAOBCYP19A1LPLLIPG | |
| SCHEMBL29400049 | 0.98 | LPL (0.57) | MAOAMAOBCYP19A1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117916657-A | Liquid crystal aligning agent, liquid crystal alignment film, method for manufacturing liquid crystal display element, and liquid crystal display element | 日产化学株式会社 | 2024-04-19 | — | — | CN | claimed |
| US-20250179031-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2025-06-05 | — | — | US | disclosed |
| CN-117940842-A | Liquid crystal aligning agent, liquid crystal alignment film, method for manufacturing liquid crystal display element, and liquid crystal display element | 日产化学株式会社 | 2024-04-26 | — | — | CN | disclosed |
| CN-117916657-A | Liquid crystal aligning agent, liquid crystal alignment film, method for manufacturing liquid crystal display element, and liquid crystal display element | 日产化学株式会社 | 2024-04-19 | — | — | CN | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| CN-116868114-A | Liquid crystal aligning agent, liquid crystal alignment film, method for manufacturing liquid crystal display element, and liquid crystal display element | 日产化学株式会社 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023147485-A2 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147485-A2 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-20030203817-A1 | High-molecular weight gel and display device | FUJI PHOTO FILM CO., LTD. | 2003-10-30 | — | — | US | disclosed |
| CN-1357052-A | Method for pretreating sample for cholesterol quantification and method for quantifying cholesterol in specific lipoprotein by using same | DAIICHI PURE CHEMICALS CO LTD (JP) | 2002-07-03 | — | — | CN | disclosed |
| CN-1344371-A | Method for quantitating cholesterol | DAIICHI PURE CHEMIALS CO LTD (JP) | 2002-04-10 | — | — | CN | disclosed |
| CN-1268185-A | Method for quantitating high density lipoprotein cholesterol | DAIICHI PURE CHEMICALS CO LTD (JP) | 2000-09-27 | — | — | CN | disclosed |
| US-5086052-A | Antiarthritic, antiallergens, antiinflammatory agents; also for asthma and psoriasis | ABBOTT LABORATORIES (US) | 1992-02-04 | — | — | US | disclosed |
| US-4970210-A | ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1990-11-13 | — | — | US | disclosed |
| EP-0299449-A2 | Pyridazinone, triazinone and oxapyridazinone lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0205272-A2 | Cinnoline derivatives | ICI AMERICAS INC. (US) | 1986-12-17 | — | — | EP | disclosed |
| US-4134917-A | Method for the denitrosation of organic nitrosamines | AMERICAN CYANAMID COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4062952-A | Substituted benzenedisulfonamides as anthelmintics | MERCK & CO., INC. (US) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179031-A1 | PROTEASOME ENHANCERS AND USES THEREOF | PSME3, PSMG3, PSME1 | MAOA 1602/4885MAOB 1646/4885CYP19A1 3443/4885 |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | MAOA 1131/4885MAOB 950/4885CYP19A1 344/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | MAOA 3294/4885MAOB 3130/4885CYP19A1 2106/4885 |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | AIFM2, FECH, GPX4 | MAOA 3630/4885MAOB 3452/4885CYP19A1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.